|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Based on c-kit and DOG-1 immunoreactivity and a PDGFRA mutation (p.Trp559_Arg560del), the tumor was diagnosed as an epithelioid variant GIST.
|
31273885 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor size, mitotic count and risk level were associated with ANO1 detection in resectable GIST patients.
|
27153560 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, a developmental small-molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro.
|
22564524 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA.
|
25766843 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since extraintestinal GIST can resemble a prostatic tumor clinically, KIT (CD117) and DOG-1 should be considered for inclusion in the immunohistochemical panel for spindle cell tumors obtained by prostate needle biopsy.
|
23057997 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DNA from tumor tissues and normal adjacent tissues was isolated and amplified for the 22 exons of PDGFRA and 26 exons of DOG1.Each PCR product was sequenced.
|
26191287 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, Ano1 depletion failed to affect tumor development in a model of colorectal cancer.
|
31383845 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, ETV1 was positive in 15 of 26 (58 %) KIT-negative GISTs and even positive in 2 cases of GIST negative for KIT and DOG1, whereas only 6 (5 %) non-GIST mesenchymal GI tumors expressed ETV1.
|
26243012 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANO1 has been demonstrated to be critical for tumor growth in breast and head and neck cancers through its regulation of EGFR signaling and pathway modulators like MAPK and protein kinase B.
|
28293832 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical investigation of the tumour located in the mesentery showed that the staining for the S-100 protein was strongly positive, while the stainings of SMA, CD34, CD117 and DOG-1 were negative.
|
29375216 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the tumor growth in nude mice implanted with GLC82 cells was significantly suppressed by ANO1 silencing.
|
26305547 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nodule was resected in an enucleation procedure; subsequent histopathologic examination revealed a low-grade, spindled cell neoplasm with diffuse immunoreactivity for CD117 (cKit) and DOG1, diagnostic of GIST.
|
31497448 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, silencing of ANO1 inhibits growth of PC-3 xenograft tumors in nude mice and induces apoptosis in tumors via upregulation of TNF-α signaling.
|
29899325 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that ANO1 knockdown significantly inhibited cell proliferation and induced cell apoptosis in either tumor cell lines or normal HaCaT cell line.
|
27732935 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-381 may function as a tumor suppressor by directly targeting TMEM16A and regulating TGF-β pathway and EMT process in the development of progression of gastric cancer.
|
28193228 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, the tumor showed variable staining in the 2 components with diffuse DOG-1 and CD117 positivity in the WD component and complete absence in the DD foci.
|
31072206 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, recent evidence indicates a role for ANO1 in cell proliferation and tumor growth.
|
24080196 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative PCR was used to explore copy number gains of specific genes (3q-PIK3CA, TP63; 11q13.3-CCND1, ANO1) in tumor DNA recovered from HPSCC (n = 48) and OPSCC (n = 52) patients.
|
27750372 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TMEM16A, a Ca<sup>2+</sup> -activated Cl<sup>-</sup> channel, contributes to tumor growth in breast cancer and head and neck squamous cell carcinoma (HNSCC).
|
28177558 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that immunohistochemical staining for DOG1, in addition to gene analysis, is useful for the diagnosis of KIT-negative tumors that are suspected to be GISTs.
|
24379641 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoplasmic staining for KIT and the absence of other GIST markers, including DOG1 and platelet-derived growth factor α, indicated that the tumor was not a GIST.
|
24938355 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, this study demonstrates that ANO1 expression is an indicator of poor prognosis of breast carcinoma patients and suggests that ANO1 might be a therapeutic target for breast carcinoma patients with ANO1-positive tumors and poor prognosis.
|
29416639 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By contrast to the original concept that DOG1 antibodies are specific to GIST neoplasms, the studies reviewed showed that the data suggest DOG1 positivity in select non-GIST tumors.
|
26678977 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alterations in the expression of I<sup>-</sup> transporters are associated with tumor development in a cancer-type-dependent manner and, accordingly, NIS, CFTR and ANO1 have been proposed as tumor markers.
|
29437784 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DOG1 is a calcium-activated chloride channel that has gained attention as a promising drug target due to its involvement in several processes essential for tumor development and progression.
|
31262867 |
2019 |